About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
The Influence of PERSEUS and IsKia Trials on Frontline Therapy Choices in MM
By
MyCancerHaven
FEATURING
Ravi Vij
,
Thomas Martin
By
MyCancerHaven
FEATURING
Ravi Vij
,
Thomas Martin
0 views
May 13, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
Featured Video
01:29
Incyte
Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD
Recommended
AUTOPLAY
ON
Related
Newest
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
17:52
Indy Hematology Review
2024 Updates on Emerging & Current Treatment of Multiple Myeloma
Feat.
K. Anderson
16:42
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…
Feat.
H. Hashmi
17:46
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …
Feat.
A. Jakubowiak
19:24
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…
Feat.
P. Richardson
24:23
MyCancerHaven
Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?
Feat.
R. Vij,
S. Al Hadidi
24:35
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …
Feat.
H. Hashmi
28:20
Indy Hematology Review
Managing Newly Diagnosed MM in 2024
Feat.
S. Usmani
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
13:15
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?…
Feat.
O. Landgren
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
13:47
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…
Feat.
B. Derman
20:19
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …
Feat.
A. Paulus
36:10
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
Feat.
S. Al Hadidi
35:37
University of Colorado Division of Hematology
2024 Updates on Multiple Myeloma Treatment
Feat.
D. Sherbenou
06:19
Insights from 2023 ASH Annual Meeting
Dara-KRd in NDMM Without ASCT: Final Analysis of a Ph2 Trial
Feat.
B. Derman
11:38
Heinz Ludwig
Maintenance Therapy in Myeloma: Which Agent and for How Long?
35:27
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
Feat.
K. Anderson
16:28
Total Health
Multiple Myeloma: A New Risk-Adapted Approach
Feat.
J. Chandler
11:02
Winship Cancer Institute - Emory University
Multiple Myeloma: Clinical Challenges for the Community Clinician
Feat.
N. Joseph
